Intralytix, Inc. and BioPhage Therapeutics Limited Partner to Develop Topical Bacteriophage Treatments of Human Wounds Infected With S. Aureus
- Category: DNA RNA and Cells
- Published on Wednesday, 05 April 2017 14:31
- Hits: 1063
BALTIMORE, MD, USA I April 4, 2017 I Intralytix, Inc. announced today that the Company is partnering with BioPhage Therapeutics Limited to develop and commercialize topical bacteriophage treatments of human wounds infected or colonized with S. aureus.
"Treatment of bacteria-infected wounds is one the most critical problems in modern medicine. Infected wounds complicate healing, often necessitate repeated surgical interventions, and may lead to amputation of extremities or even death. The problem is compounded by the increasing emergence of multi-antibiotic-resistant bacteria – such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) - that may colonize the wounds and make their successful treatment very difficult or even impossible to achieve," stated Dr. Alexander Sulakvelidze, Intralytix's Chief Scientist. "The ultimate goal of our partnership with BioPhage is to develop and make commercially available a novel phage-based topical treatment approach for managing wounds infected with S. aureus, including wounds infected with multidrug-resistant or pan-resistant strains (i.e., strains resistant to all major classes of antibiotics)," Dr. Sulakvelidze added.
"We view this partnership as an important step in developing phage-based products for managing wounds infected with S. aureus," stated John Woloszyn, Intralytix's CEO. "Working with BioPhage Therapeutics, we aim to rapidly bring our bacteriophage technology to the market, and to offer a natural, safe, and effective antimicrobial approach to millions of people suffering from infected, hard-to-heal wounds," Mr. Woloszyn added.
Intralytix, Inc. is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety, animal health, human therapeutics, and dietary supplements and probiotics. The Company has the world's largest portfolio of FDA-approved phage preparations for food safety applications and is involved in the development of several additional products for human therapeutic, veterinary medicine, probiotic, and other applications.
BioPhage Therapeutics Limited is a British company with strong skills in the clinical development, registration, and marketing of therapeutic drug products. "The partnership with Intralytix is ideal," stated Robert Jackson, Chairman of BioPhage. "We can build upon Intralytix's strength in bacteriophage science by formulating their phage into a drug product that will be in clinical trials at leading UK teaching hospitals by the end of the year."